Overview

Influence of Bosentan on the Pharmacokinetics of Nintedanib

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The trial was designed to investigate whether, and to which extent, multiple doses of bosentan may influence the plasma levels of nintedanib administered as a single dose.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bosentan
Nintedanib